VEGFA and cancer: The discovery that galectins, which bind β-galactoside sugars on glycoproteins, bind specific glycosylated forms of VEGFR-2, trigger receptor activation, and mediate resistance to anti-VEGF therapies used to treat cancer, represents a major shift in understanding and targeting VEGFR-2 signaling in cancer and other angiogenesis-associated diseases [15,16].